Answers are grounded in this paper and cite their sources.
Since the beginning of the Coronavirus Disease 2019 (COVID-19) pandemic, the most severe symptoms have occurred in elderly patients with comorbidities, with a higher risk of complications. Prescribed drugs, which are already part of geriatric care, associated with the experimental therapeutic drugs of COVID-19, may increase the risk of undesirable occurrences, due to the practice of polypharmacy, with the possibility of emergence of inappropriate adverse events and drug interactions. This can increase the risk of worsening the clinical picture, impairment of the general condition, intensification of inflammation and associated unfavorable conditions, incurring the highest probability of mortality.
No takes yet. Share an insight, caveat, or question.
Andrade et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: